Minutiello L
Servizio di Cardiologia, Regione Marche, Unità Sanitaria Locale n. 20, Presidio Ospedaliero di Camerino.
Minerva Cardioangiol. 1994 Mar;42(3):119-22.
We assessed the safety and efficacy of intravenous propafenone in the treatment of atrial fibrillation and flutter of recent onset (1-10 days). The drug was administered, at a dosage of 2 mg/kg, to 46 consecutive patients (with age variable from 35 to 86 years), 36 with atrial fibrillation, 10 with atrial flutter. The efficacy of propafenone was influenced by the interval from the onset of the arrhythmia and the start of therapy. All patients underwent echocardiographic control: mean left atrial dimensions were non significantly different in responders and non responders. Serious hypotension developed in two patients, regressed with appropriate therapy. Non responders showed a significant reduction of ventricular rate. By synthesis, propafenone is a safe and effective drug for treatment of atrial fibrillation or flutter of recent onset, in refractory patients it allows however an adequate control of ventricular rate.
我们评估了静脉注射普罗帕酮治疗近期发作（1 - 10天）的心房颤动和心房扑动的安全性和有效性。该药物以2mg/kg的剂量连续给予46例患者（年龄在35至86岁之间），其中36例为心房颤动，10例为心房扑动。普罗帕酮的疗效受心律失常发作至治疗开始的时间间隔影响。所有患者均接受超声心动图检查：反应者和无反应者的平均左心房大小无显著差异。两名患者出现严重低血压，经适当治疗后恢复。无反应者的心室率显著降低。综合来看，普罗帕酮是治疗近期发作的心房颤动或心房扑动的安全有效药物，然而在难治性患者中它能充分控制心室率。
